PHAS stock has been on fire over the past month, gaining over 440% during this period. Today PhaseBio Pharmaceuticals (NASDAQ:PHAS) is valued at more than $350 million. This week, PHAS stock leaped 32.5% after the company made some milestone announcements about its drug pipeline.
Breakthrough Therapy Designation for PB2452The first major milestone announced by the company is the receiving of Breakthrough Therapy Designation for PB2452 from the US Food and Drug Administration. PhaseBio has also reported that they have issued a license to ImmunoForgePB1023 in age-related muscle loss diseases but will retain all development rights ...
Read The Full Article On MicroSmallCap.com
Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.
All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.